Method and devices for cellular transfer of compounds with augmented reality application

ABSTRACT

The embodiments disclose a method, including suspending cannabinoid compound molecules and constituents in an aqueous solution, suspending Aloe Vera molecules and its constituents in an aqueous solution, wherein a combination of cannabinoid compound molecules and constituents and Aloe Vera molecules and its constituents may be used for suspending in an aqueous solution, encapsulating cannabinoid compound molecules and Aloe Vera molecules within a liposome in an aqueous solution, and blending the liposome encapsulated cannabinoid compound molecules and Aloe Vera molecules with other ingredients into a health beneficial product and delivery system for oral including sublingual ingestion and nasal spray and suppository insertion or topical application with a plurality of nano sensors by humans.

BACKGROUND

Delivery methods of medically beneficial products can a difference in whether a person will take the medically beneficial products. How the medically beneficial products ingredients are prepared affects the forms of delivery available to make the person consuming the medically beneficial products and can affect the potency and medical benefit efficacy.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A shows for illustrative purposes only an example of a method and devices for cellular transfer of compounds with augmented reality application of one embodiment.

FIG. 1B shows for illustrative purposes only an example of a liposome lipid chemical structure of one embodiment.

FIG. 2A shows for illustrative purposes only an example of a liposome encapsulated CBD compound of one embodiment.

FIG. 2B shows for illustrative purposes only an example of a liposome encapsulated Aloe Vera compound of one embodiment.

FIG. 2C shows for illustrative purposes only an example of a liposome encapsulated Inflacin compound of one embodiment.

FIG. 2D shows for illustrative purposes only an example of liposome encapsulated CBD, Aloe Vera, and Inflacin compounds of one embodiment.

FIG. 3A shows for illustrative purposes only an example of a chemical structure of Aloe Vera compound emodin of one embodiment.

FIG. 3B shows for illustrative purposes only an example of a chemical structure of Aloe Vera compound aleosin of one embodiment.

FIG. 3C shows for illustrative purposes only an example of a chemical structure of Aloe Vera compound acemannan of one embodiment.

FIG. 4A shows for illustrative purposes only an example of a chemical structure of CBD of one embodiment.

FIG. 4B shows for illustrative purposes only an example of a chemical structure of THC of one embodiment.

FIG. 5A shows for illustrative purposes only an example of a liposome 3D structure of one embodiment.

FIG. 5B shows for illustrative purposes only an example of a liposome encapsulated molecule of one embodiment.

FIG. 6 shows a block diagram of an overview of a liposome delivery system of combined Aloe Vera components and cannabis components of one embodiment.

FIG. 7 shows for illustrative purposes only an example of a liposome attaching to human cell and both opening for transfer of Aloe Vera and CBD into the human cell of one embodiment.

FIG. 8 shows a block diagram of an overview of examples of liposome cannabis product benefits of one embodiment.

FIG. 9 shows a block diagram of an overview of continuation of examples of liposome cannabis product benefits of one embodiment.

FIG. 10 shows a block diagram of an overview of examples of cannabinoid component product benefits of one embodiment.

FIG. 11 shows a block diagram of an overview of examples of CBD component product benefits of one embodiment.

FIG. 12 shows a block diagram of an overview of examples of Aloe Vera component product benefits of one embodiment.

FIG. 13 shows for illustrative purposes only an example of nano sensors suspended in an encapsulation delivery application of one embodiment.

FIG. 14 shows for illustrative purposes only an example of liposome delivery system cellular transfer into a user's skin of one embodiment.

FIG. 15 shows for illustrative purposes only an example of a cellular transfer augmented reality application previewing treatment potential results of one embodiment.

FIG. 16 shows for illustrative purposes only an example of a liposome lipid processing devices for encapsulating compounds and creating application delivery products of one embodiment.

DETAILED DESCRIPTION OF THE INVENTION

In a following description, reference is made to the accompanying drawings, which form a part hereof, and in which is shown by way of illustration a specific example in which the invention may be practiced. It is to be understood that other embodiments may be utilized and structural changes may be made without departing from the scope of the present invention.

General Overview:

It should be noted that the descriptions that follow, for example, in terms of a method and devices for cellular transfer of compounds with augmented reality application is described for illustrative purposes and the underlying system can apply to any number and multiple types encapsulated molecules. In one embodiment of the present invention, the method and devices for cellular transfer of compounds with augmented reality application can be configured using a combination of CBD and Aloe Vera. The method and devices for cellular transfer of compounds with augmented reality application can be configured to include only encapsulated CBD molecules and can be configured to include only encapsulated Aloe Vera molecules using the present invention.

FIG. 1A shows for illustrative purposes only an example of a method and devices for cellular transfer of compounds with augmented reality application of one embodiment. FIG. 1A shows a bilayer liposome 100. The bilayer liposome 100 is shown in a 2D illustration encapsulating CBD molecules 110 and Aloe Vera molecules 120. The spherical liposome shape is formed by the hydrophobic tail 130 and hydrophilic head 140 of its compounds in an aqueous solution 150. Cannabinoid compounds including the CBD molecules 110 and Aloe Vera molecules 120 are suspended in the aqueous solution 150 and encapsulated while the liposome is forming of one embodiment.

FIG. 1A shows a liposome encapsulation of CBD and Aloe Vera molecules in combination. In other embodiments the liposome encapsulation may be used to encapsulate CBD molecules alone and Aloe Vera molecules alone. Separate liposome encapsulation of the two ingredients provides a method in which the proportioning of the separated CBD and Aloe Vera liposome encapsulations may be used to increase the health benefits of each for a specific purpose for a specific medical condition.

For example a treatment product that is targeted for persons suffering from depression may receive the benefits of CBD constituents that treat depression in a larger proportion than Aloe Vera constituents that treat depression based on studies on the efficacy of the different constituents for the treatment of depression of one embodiment. A device may be used for blending varying proportions of separately encapsulated cannabinoid compound molecules and Aloe Vera molecules for increasing health benefits of each for a specific purpose for a specific medical condition. The device may be coupled to a digital server, a plurality of databases and a computer.

The plurality of databases have recorded and stored data on varying proportional formulations of cannabinoid compound molecules and Aloe Vera molecules and their benefits for various medical conditions. The computer is used for querying the database for a specific medical condition and the cannabinoid and Aloe Vera constituent benefits. The digital server is used to instruct the blending device to blend with the liposome lipid in an aqueous solution proportional quantities of the various constituents using the varying proportional formulations of cannabinoid compound molecules and Aloe Vera molecules for blending a beneficial product and delivery system for a human to use for treatment of the specific medical condition of one embodiment.

Liposome Lipid Chemical Structure:

FIG. 1B shows for illustrative purposes only an example of a liposome lipid chemical structure of one embodiment. FIG. 1B shows an example of one lipid chemical structure 160. The liposomes may be made of other lipid chemical structures of lipid compounds used for creating lipid 170 liposomes. The liposomes created from the lipid compounds and methods are characterized by the ability to inhibit biological activity, open readily due to a change in pH, may open readily due to a change in photo intensity and other characteristics that facilitate the delivery of the encapsulated molecules of one embodiment.

DETAILED DESCRIPTION

FIG. 2A shows for illustrative purposes only an example of a liposome encapsulated CBD compound of one embodiment. FIG. 2A shows the bilayer liposome 100 in a 2D illustration encapsulating CBD molecules 110. The bilayer liposome 100 encapsulated CBD molecules 110 form a base for a delivery system for products for consumption by humans. CBD provides a variety of benefits. Some of the benefits include treating anorexia, cachexia, gastrointestinal disorders, and nausea, appetite loss, control diabetes, treat Crohn's symptoms, Mood/behavior conditions, depression, Anxiety, control ADD/ADHD, stress, bipolar, OCD, PTSD, treating asthma, fatigue, hypertension, glaucoma, HIV/Aids, muscular dystrophy, providing relief from cancer and cancer treatment symptoms of one embodiment

Liposome Encapsulated Aloe Vera Compound:

FIG. 2B shows for illustrative purposes only an example of a liposome encapsulated Aloe Vera compound of one embodiment. FIG. 2B shows the bilayer liposome 100 in a 2D illustration encapsulating Aloe Vera molecules 120. The bilayer liposome 100 encapsulated Aloe Vera molecules 120 form a base for a delivery system for products for consumption by humans.

Aloe vera is a rich source of over 200 naturally occurring nutrients which contain water soluble and fat soluble vitamins, minerals, enzymes, polysaccharides, phenolic compounds and organic acids. Its secondary metabolites have multiple properties such as anti-inflammatory, antibacterial, antioxidant, immune boosting, anticancer, antiaging, sunburn relief and antidiabetic potentials. Several traditional uses also have been reported such as burn injury, eczema, cosmetics, inflammation, and fever. Nine categories of phytochemical constituents of Aloe vera can be classified as, anthraquinones, inorganic compounds, amino acids, fatty acids, alkaloids, carbohydrates, enzymes, and vitamins along with other miscellaneous compounds.

Aloe vera contains 75 potentially active constituents: vitamins, enzymes, minerals, sugars, lignin, saponins, salicylic acids and amino acids. Aloe vera vitamins include vitamins A (beta-carotene), C and E, which are antioxidants and vitamin B12, folic acid, and choline. Aloe vera enzymes include aliiase, alkaline phosphatase, amylase, bradykinase, carboxypeptidase, catalase, cellulase, lipase, and peroxidase. Bradykinase helps to reduce excessive inflammation when applied to the skin topically, while others help in the breakdown of sugars and fats.

Aloe vera minerals include calcium, chromium, copper, selenium, magnesium, manganese, potassium, sodium and zinc. Aloe vera sugars include monosaccharides (glucose and fructose) and polysaccharides (glucomannans/polymannose). These are derived from the mucilage layer of the plant and are known as mucopolysaccharides. The most prominent monosaccharide is mannose-6-phosphate, and the most common polysaccharides are called glucomannans [beta-(1,4)-acetylated mannan]. Acemannan, a prominent glucomannan has also been found. A glycoprotein with antiallergic properties, called alprogen and novel anti-inflammatory compound, C-glucosyl chromone has been isolated from Aloe vera gel.

Aloe vera anthraquinones include phenolic compounds traditionally known as laxatives and Aloin and emodin act as analgesics, antibacterials and antivirals. Aloe vera fatty acids include 4 plant steroids; cholesterol, campesterol, β-sisosterol and lupeol. All these have anti-inflammatory action and lupeol also possesses antiseptic and analgesic properties. Aloe vera hormones include auxins and gibberellins that help in wound healing and have anti-inflammatory action. Aloe vera other potentially active constituents include 20 of the 22 human required amino acids and 7 of the 8 essential amino acids. It also contains salicylic acid that possesses anti-inflammatory and antibacterial properties. Lignin, an inert substance, when included in topical preparations, enhances penetrative effect of the other ingredients into the skin. Saponins that are the soapy substances form about 3% of the gel and have cleansing and antiseptic properties.

One example of the benefits of Aloe Vera is found in the use of Aloe Vera juice mixed with water and honey used as an effective antimalarial cure in Yemen. There are many other reported and studied uses and benefits throughout the world of one embodiment.

Some studies characterize the Aloe Vera phytochemical constituents of anthraquinones as one of the most important active ingredients of Aloe Vera. The antiplasmodial activity of Aloe Vera may be explained in the light of the presence of anthraquinones and other quinoid compounds which exert good activity against P. falciparum. The four main anthraquinones showing quite high medical values are acemannan, aloe-emodin, aloe bitter and aloe lectin of one embodiment.

Liposome Encapsulated Inflacin Compound:

FIG. 2C shows for illustrative purposes only an example of a liposome encapsulated Inflacin compound of one embodiment. FIG. 2C shows the bilayer liposome 100 in a 2D illustration encapsulating Inflacin molecules 200. The bilayer liposome 100 encapsulated Inflacin molecules 200 form a base for a delivery system for products for consumption by humans. A group of compounds called Inflacin may be topically applied to alleviate pain associated with arthritis and increased joint mobility.

Inflacin provides its analgesic benefit when applying the topical cream to areas of the body affected by stiffness, soreness and pain. These include: hands, feet, knees and shoulders and muscles of the neck, arms, legs and back. Liposome encapsulated Inflacin in for example a topical cream delivers rapid absorption through the skin cells to deliver pain relief and increased mobility for example hand gripping within minutes of one embodiment.

Liposome Encapsulated CBD, Aloe Vera, and Inflacin Compounds:

FIG. 2D shows for illustrative purposes only an example of liposome encapsulated CBD, Aloe Vera, and Inflacin compounds of one embodiment. FIG. 2D shows the bilayer liposome 100 in a 2D illustration encapsulating CBD molecules 110, Aloe Vera molecules 120, and Inflacin molecules 200. These three compounds may be included in the liposome encapsulation process singularly, or in any combination of two or all three as shown. The liposome encapsulation process may also include other compounds for example other cannabinoids for targeting specific medical benefits for specific conditions and symptoms of one embodiment.

Chemical Structure of Aloe Vera Compound Emodin:

FIG. 3A shows for illustrative purposes only an example of a chemical structure of Aloe Vera compound emodin of one embodiment. FIG. 3A shows a chemical structure of Aloe Vera compound emodin 300. An emodin 302 molecule as shown in the chemical structure of Aloe Vera compound emodin 300 contains anthraquinones that generate reactive oxygen and thus inactivate malaria parasites. Emodin 302 also provides beneficial properties for immunity and inflammation, antioxidant property, inflammatory bowel disease, supportive care of heart failure/function, hypertension and related disorders, diabetes mellitus, aging-related neurological diseases, atopic dermatitis, hepatic inflammation, autoimmune disorders including rheumatoid arthritis and autoimmune diabetes mellitus, renal inflammatory conditions, and infectious diseases of one embodiment.

Chemical Structure of Aloe Vera Compound Aleosin:

FIG. 3B shows for illustrative purposes only an example of a chemical structure of Aloe Vera compound aleosin of one embodiment. FIG. 3B shows a chemical structure of Aloe Vera compound aleosin 310. An aleosin 312 molecule as shown in the chemical structure of Aloe Vera compound aleosin 310 and is an active constituent of the herb Aloe Vera. Aloesin suppresses cell growth and metastasis in ovarian cancer SKOV3 cells through the Inhibition of the MAPK Signaling Pathway, and plays a crucial role in anti-inflammatory activity, ultraviolet protection, and antibacterium. Aloesin accelerates skin wound healing by modulating MAPK/Rho and Smad signaling pathways, has antioxidant properties, provides a significant beneficial effect in lowering blood glucose and improving insulin resistance in humans, and the activity of aloesin increases adiponectin production and improves the insulin sensitivity of one embodiment.

Chemical Structure of Aloe Vera Compound Acemannan:

FIG. 3C shows for illustrative purposes only an example of a chemical structure of Aloe Vera compound acemannan of one embodiment. FIG. 3C shows a chemical structure of Aloe Vera compound acemannan 320. Acemannan 322 is found in the Aloe Vera plant. Acemannan 322 has various properties and benefits including helps cells to be more resistant to viruses and pathogenic bacteria, improves overall cellular metabolism and functioning, promotes healthy inflammation response, provides critical lubrication of joints, aids in the absorption of water, minerals, and nutrients in the GI tract, reduces pain, improves vascular flow, reduces scarring, increases the body's own production of interferon, interleukins, increase the number of antibody forming T-cells in the spleen, increases the number and activity of killer T-cell and increase monocyte activity, soothes and promotes healing of intestinal disorders such as indigestion, heartburn, hyper-acidity, peptic and duodenal ulcers, colitis, and hemorrhoids, promotes healthy kidney function, speeds wound healing, reduces allergic reactions, stimulates bone marrow activity, anti-aging properties, and supports healthy blood pressure of one embodiment.

Chemical Structure of CBD:

FIG. 4A shows for illustrative purposes only an example of a chemical structure of CBD of one embodiment. FIG. 4A shows a chemical structure of CBD 400 with a molecular name of cannabidiol (CBD) 410. The illustration shows a hydroxyl group 420 bonded to one of a group of carbon atom cyclic rings that create the bonds for the branch and chain structures of one embodiment.

Chemical Structure of THC:

FIG. 4B shows for illustrative purposes only an example of a chemical structure of THC of one embodiment. FIG. 4B shows a chemical structure of THC 430. This chemical structure of THC 430 has a molecular name of tetrahydrocannabinol (THC) 440. The illustration shows the carbon atom cyclic ring 450 structures that create the branch bonds. THC 430 is not a legal compound federally. Its use may only be legal in States and only within that State that has legalized its use. Therefore the embodiments of this invention may exclude the addition of THC 430 where it is not legal without changing the method or non-THC embodiments. CBD derived from hemp is federally legal. CBD may also be derived from non-hemp cannabis plants and must meet minimum THC 430 levels to be used for interstate purposes of one embodiment.

Liposome 3D Structure:

FIG. 5A shows for illustrative purposes only an example of a liposome 3D structure of one embodiment. FIG. 5A shows a liposome 3D structure 500. The liposome 3D structure 500 is formed during a liposome CBD-Aloe Vera process cell disruption operation. FIG. 5A shows an internal aqueous compartment 510 is created when the hydrophobic tail 130 and hydrophilic head 140 elements of lipid materials are aligned during the cell disruption operation. The liposome 3D structure 500 can be seen to be spherical. The hydrophobic tail 130 and hydrophilic head 140 alignments also form bonds between the hydrophilic head 140 elements and the hydrophobic and hydrophilic attractions and repulsions cause the spherical associations of the lipid elements of one embodiment.

Liposome Encapsulated Molecule:

FIG. 5B shows for illustrative purposes only an example of a liposome encapsulated molecule of one embodiment. FIG. 5B shows the liposome 3D structure 500. The liposome 3D structure 500 forms a bilayer vesicle with an internal void. The liposome CBD-Aloe Vera process suspends molecules of a component in an aqueous solution as illustrated by a liposome encapsulated molecule 520. The suspended molecule fills the internal void during cell disruption and becomes encapsulated as the liposome completes the formation of the bilayer vesicle of one embodiment.

Liposome Delivery System of Combined Aloe Vera Components and Cannabis Components:

FIG. 6 shows a block diagram of an overview of a liposome delivery system of combined Aloe Vera components and cannabis components of one embodiment. FIG. 6 shows a liposome delivery system of Aloe Vera components 600 emodin 302, aloesin 312 and acemannan 322. A liposome delivery system of combined Aloe Vera components and cannabis components 610 including emodin 302, aloesin 312, acemannan 322, CBD 400 and THC 430. A liposome delivery system of cannabinoid and cannabis components 620 with CBD 400 and THC 430. Other liposome delivery system components including lanolin, retinol, vitamin e, anti-wrinkle creams and treatments for transporting liposome encapsulated ingredients 625.

It should be understood that the selection of both Aloe Vera components and cannabis components can be formulated as any of the components alone or in various combinations of components from each group of Aloe Vera components and cannabis components. The products for oral sublingual ingestion and nasal spray, and suppository insertion and tampon vaginal insertion 630 or topical applications including underarm topical application 640 may be formulated for targeting specific medical benefits for specific conditions and symptoms. For example as shown in FIG. 12 Aloe Vera has anti-inflammatory properties 1237 and cannabis components of a combined group of CBC, CBD, CBDA, CBG, CBN, THC, THCA 925 relieves and reduces arthritis, inflammation 935.

A liposome delivery system may include products for oral sublingual ingestion and nasal spray, and suppository insertion and tampon vaginal insertion 630 or topical applications including underarm topical application 640. Liposome delivery system products for oral including sublingual ingestion and nasal spray may include at least one of a group beverages, flavored beverages, pills, capsules, tablets and sprays and for suppository insertion include rectal suppositories used by humans. Liposome delivery system products for topical applications including underarm topical application 640 include at least one of a group of forms including creams, gels, ointments, salves, sprays, powders, serums, liquids, toners, and oils for use in cosmetics, first aid, and sunscreens by humans.

A liposome delivery system in topical applications including underarm topical application 640 may be formulated with these combined Aloe Vera and cannabis components to target arthritic inflammation where a topical cream is formed for applying to a person's hands that are suffering from arthritis of one embodiment.

Liposome Attaching to Human Cell and Both Opening for Transfer of Aloe Vera and CBD into the Human Cell:

FIG. 7 shows for illustrative purposes only an example of a liposome attaching to human cell and both opening for transfer of Aloe Vera and CBD into the human cell of one embodiment. FIG. 7 shows a liposome encapsulated Aloe Vera and CBD 700 liposome attached to a human cell. FIG. 7 shows a liposome attaching to a human cell and both bilayer structures opening for transfer of Aloe Vera and CBD into the human cell 730. A human cell membrane is composed of a lipid bilayer structure. The human cell membrane lipid molecules each have a hydrophilic and a hydrophobic end. Rapid absorption occurs with the liposome bilayer spreading over a human cell. The liposome encapsulating bilayer structure 710 begins to breach as does the human cell 720 membrane upon contact. The liposome bilayer with the encapsulated material reacts with the human cell membrane bilayer wherein the hydrophobic characteristic of the hydrophobic tail grouping creates a breach in the human cell membrane. The encapsulated material passes through the breach into the human cell and the human cell material passes through the breach into newly created voids of the vesicle interior filling the void left by the passing encapsulated material thereby accelerating the rate of the transfer of substances. Once the transfers of the substances are completed the bilayer collapses across the surface of the human cell membrane resealing the human cell membrane and the excess bilayer material is absorbed and excreted through normal bodily functions of one embodiment.

Examples of Liposome Cannabis Product Benefits:

FIG. 8 shows a block diagram of an overview of examples of liposome cannabis product benefits of one embodiment. FIG. 8 shows examples of liposome cannabis product benefits 800 in different groupings of medical conditions and symptoms. For example conditions related to gastrointestinal 810 involvements. A combination of cannabis product components CBD, THC 820 is used to treat anorexia, cachexia, gastrointestinal disorders, and nausea 830. CBN, THC 822 reduces appetite loss 832. A combination of CBD, THCV 824 helps control diabetes 834. CBD, THC 826 is used to treat Crohn's 836 symptoms of one embodiment.

Mood/behavior 840 conditions are treated using a combination of CBC, CBD, CBG, CBN, and THC 850 for depression 860. CBD, CBG 852 is used to treat anxiety 862.

CBD, THC 854 helps control ADD/ADHD, stress 864, attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD). The combination of CBD, CBG, and THC 856 is used to treat bipolar, OCD, PTSD 866, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) of one embodiment.

Other 870 conditions and symptoms include the use of CBD, THC 880 for treating asthma, fatigue, hypertension 890, and CBG, THC 881 for glaucoma 891. Another combination of CBD, THC, THCA 882 for treatment of HIV/Aids 892. Treatments with CBC, CBD, CBG, and THC 883 are beneficial for muscular dystrophy 893. The liposome cannabis product combination of components CBC, CBD, CBDA, CBG, THC, and THCA 884 is used for providing relief from cancer 894 and cancer treatment symptoms of one embodiment. The benefits are further described in FIG. 9 .

Continuation of Examples of Liposome Cannabis Product Benefits:

FIG. 9 shows a block diagram of an overview of continuation of examples of liposome cannabis product benefits of one embodiment. FIG. 9 shows continuing from FIG. 8 a continuation of examples of liposome cannabis product benefits 900. Medical conditions that affect pain/sleep 910 can benefit from combinations of cannabis product components for example CBD, THC 920 for treating sleep apnea 930; CBD, THC 921 for reduced cramps, migraine/headache, phantom limb, spinal injury 931. CBD, CBN, THC 922 is used to treat fibromyalgia 932. CBC, CBD, CBN, THC 923 provides relief for insomnia 933. The combination of CBC, CBD, CBN, THC, and THCV 924 reduces pain 934. The combined group of CBC, CBD, CBDA, CBG, CBN, THC, and THCA 925 relieves and reduces arthritis, inflammation 935.

Neurological 940 conditions are treated using liposome combinations of cannabis product components. CBD, THC 950 is used to treat Tourette's 960 syndrome symptoms. CBD, CBN, THCA, THCV 951 help control epilepsy, seizures 961 onsets. CBCD, CBN, THC, THCA 952 is used to treat the symptoms of multiple sclerosis 962.

The combination of CBC, CBD, CBG, THC, and THCA 953 is used to treat Alzheimer's, Parkinson's 963. CBD, CBG, CBN, THC, THCA 954 reduces spasticity 964. CBC, CBD, CBG, CBN, THCV 955 benefit osteoporosis 965 effects. CBC, CBD, CBG, CBN, THC, THCA 956 is used to treat ALS 966, Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease of one embodiment.

Examples of Cannabinoid Component Product Benefits:

FIG. 10 shows a block diagram of an overview of examples of cannabinoid component product benefits of one embodiment. FIG. 10 shows examples of cannabinoid component product benefits 1000. CBDA 1001 is a cannabinoid component that reduces inflammation 1002 and inhibits cancer cell growth 1003. CBG 1030 is a cannabinoid component that aids sleep 1031, inhibits cancer cell growth 1032, and promotes bone growth 1033. Another cannabinoid component is CBGA 1010 that reduces inflammation 1011, relieves pain 1012, and slows bacterial growth 1013. Yet another cannabinoid component is CBC 1040 with properties that inhibits cancer cell growth 1041, promotes bone growth 1042, reduces inflammation 1043, and relieves pain 1044. One of the cannabinoid components is CBCA 1020 that reduces inflammation 1021 and treats fungal infection 1022. Still another one of the group of cannabinoid components is CBN 1050 that reduces inflammation 1051, relieves pain 1052, aids sleep 1053, is an appetite stimulant 1054, and is an anti-convulsive 1055 of one embodiment.

Examples of CBD Component Product Benefits:

FIG. 11 shows a block diagram of an overview of examples of CBD component product benefits of one embodiment. FIG. 11 shows examples of CBD component product benefits 1100. CBD 1110 benefits include properties that promotes function in the immune system 1120, reduces small intestine contractions 1121, reduces vomiting and nausea 1122, suppresses muscle spasms 1123, vasorelaxant 1124, tranquillizing 1125, relieves pain 1126, relieves anxiety 1127, treats psoriasis 1128, reduces inflammation 1130, reduces seizures and convulsions 1131, reduces risk of artery blockage 1132, reduces blood sugar levels 1133, inhibits cancer cell growth 1134, promotes bone growth 1135, slows bacterial growth 1136, neuro-protective 1137, and antibacterial 1138 of one embodiment.

Examples of Aloe Vera Component Product Benefits:

FIG. 12 shows a block diagram of an overview of examples of Aloe Vera component product benefits of one embodiment. FIG. 12 shows examples of Aloe Vera component product benefits 1200. Aloe vera 1210 is a succulent has been used for health purposes, dating back to ancient Egypt. The Aloe vera 1210 plant is grown in tropical climates worldwide. It is known for relieving heartburn to potentially slowing the spread of breast cancer, researchers are just beginning to unlock the benefits of this universal plant and its many byproducts.

Aloe vera 1210 has benefits that include antioxidant and antibacterial properties 1220, lowers the triglyceride levels among people with type 2 diabetes 1221, accelerates the healing of burns 1222, reduces dental plaque 1223, improve skin and prevent wrinkles 1224, lowers blood sugar levels in diabetics 1225, reduce hair loss 1226, relieve psoriatic arthritis symptoms 1230, treat acne lesions 1231, keeping skin hydrated and clear 1232, treat skin burns 1233, reduce itchiness and inflammation 1234, a pain reliever salicylic acid found in Aloe Vera 1235, treat hemorrhoids 1236, and anti-inflammatory properties 1237 of one embodiment.

Nano Sensors Suspended in an Encapsulation Media:

FIG. 13 shows for illustrative purposes only an example of nano sensors suspended in an encapsulation delivery application of one embodiment. FIG. 13 shows a plurality of nano sensors 1300 suspended in delivery application 1310 of a liposome encapsulation of CBD molecules 110 and Aloe Vera molecules 120 in a bilayer liposome 100. The plurality of nano sensors 1300 will be included in a liposome encapsulation of compounds delivery application media 1320 for example a cream for external delivery of the encapsulated compounds for example topical creams. The plurality of nano sensors 1300 may include temperature sensors, chemical analyzing sensors and other sensors to determine the biological conditions in the cells. The plurality of nano sensors 1300 may be read using an external device. The external device may include a user digital device with a cellular transfer augmented reality application installed. The external device will receive and process the data gathering results of the plurality of nano sensors 1300 determinations and prepare a digital and printed report for a user's physician's evaluation for one embodiment.

Liposome Delivery System Cellular Transfer into a User's Skin:

FIG. 14 shows for illustrative purposes only an example of liposome delivery system cellular transfer into a user's skin of one embodiment. FIG. 14 shows a user with forehead wrinkles 1400. The user has applied a topical application of the liposome delivery system cellular transfer compounds. An initial liposome opening to transfer compounds into user cells 1410 takes place open application to the user's skin. A 3 d depth camera 1420 is used for capturing images of user's forehead 1425. After the initial period of time wrinkles are beginning to fade 1430. Liposome released compounds are penetrating deeper into the user's skin 1440.

The 3d depth camera 1420 is capturing images of wrinkles beginning to fade 1455. When the liposome released compounds are fully penetrating deeper into user's skin 1470 the user's forehead wrinkles are significantly lessened in prominence 1460. The 3d depth camera 1420 has been capturing images of the significantly faded wrinkles on the user's forehead 1485. The user's application of the topical cream of the liposome delivery system cellular transfer compounds has quickly and effectively reduced the user's forehead wrinkles of one embodiment.

Cellular Transfer Augmented Reality Application Previewing Treatment Potential Results:

FIG. 15 shows for illustrative purposes only an example of a cellular transfer augmented reality application previewing treatment potential results of one embodiment. FIG. 15 shows a cellular transfer network 1500 including a digital server 1510, plurality of databases 1520, a cellular transfer augmented reality application 1530 installed on a cellular transfer network computer 1540 and an artificial intelligence 1550 module. A user may connect to the cellular transfer network 1500 via the internet 1560 using a user's digital device with depth camera 1570 with the cellular transfer augmented reality application 1530 installed. In this example the user with forehead wrinkles 1400 can use the depth camera to provide a “before” 3D photograph of the wrinkles. The cellular transfer network 1500 artificial intelligence 1550 module can produce an Augmented Reality (AR) 3D preview for the user to allow the user to see at least an average result using data stored on the plurality of databases 1520. Augmented Reality (AR) is a live, direct or indirect view of a physical, real-world environment whose elements are augmented (or supplemented) by computer-generated sensory input such as sound, video, graphics or GPS data. In this instance the user will see the progress of the wrinkles fading in real time after the application of the topical cream with the liposome delivery system cellular transfer compounds. The user is made aware that their results may differ but based on their physical conditions input this is the possible outcome of one embodiment.

Liposome Lipid Processing Devices for Encapsulating Compounds and Creating Application Delivery Products:

FIG. 16 shows for illustrative purposes only an example of a liposome lipid processing devices for encapsulating compounds and creating application delivery products of one embodiment. FIG. 16 shows the cellular transfer network 1500, digital server 1510, plurality of data bases 1520, cellular transfer augmented reality application 1530 and cellular transfer network computer 1540 controlling the production of the lipid liposome encapsulation process and additional processing to create the application delivery products. The artificial intelligence cloud 1610 monitoring the processing conditions including temperatures, ingredient proportioning to the volume of liposome volume and can adjust those factors to produce a predetermine formulation of the products. Cellular transfer network 1500 processes controls 1620 are connected to the processing devices using a processes controls interface 1630. For example the temperature of a container sterilization processor 1632 is adjusted for the predetermined container type and materials to prevent damaging the container. A phospholipids supply tank 1640, CBD supply tank 1642 for example and an Aloe Vera supply tank 1644 for example are shown to convey those compounds into the pre-disrupting liposome combination chamber 1650. Disrupting processes 1660 create the conditions for the formation of the liposomes and encapsulation of the compounds in this illustration CBD and Aloe Vera. Depending on the final product being produced for example a production line will include for example a beverage liquid or topical cream supply tank 1646. A sterilizing mixing tank 1665 is used to blend the liposome encapsulated compounds with the product delivery ingredient. A mixture temperature controller and filling pump with digital valve 1670 measures the filling of the beverage containers or topical cream pump containers 1672 and upon completion initiates a container capping processor 1674. After capping the containers are processed for packaging 1680 of one embodiment.

The foregoing has described the principles, embodiments and modes of operation of the present invention. However, the invention should not be construed as being limited to the particular embodiments discussed. The above described embodiments should be regarded as illustrative rather than restrictive, and it should be appreciated that variations may be made in those embodiments by workers skilled in the art without departing from the scope of the present invention as defined by the following claims. 

1-20. (canceled)
 21. A drug treatment assay system, comprising: a purification device configured for detecting and isolating live cancer cells from dead cancer cells and non-cancer cells of a patient biopsy sample; a testing device coupled to the purification device configured to infuse at least one drug treatment to the live cancer cells; an optical density device coupled to the testing device configured for measuring a rate of death of the live cancer cells at different intervals for a predetermined period of time after infusion of the at least one drug treatment; a processor coupled to the optical density device configured for analyzing measured rates of death of the live cancer cells; and at least one computer coupled to the processor configured for using analyzed rate of death results, specific patient genetic markers associated with cancer and drug resistance and allergies to generate and transmit clinician treatment recommendations for the patient's treatment based on the analyzed rate of death results of the live cancer cells testing.
 22. The drug treatment assay system of claim 21, wherein the clinician treatment recommendations are used to assess anti-inflammatory therapies.
 23. The drug treatment assay system of claim 21, wherein the clinician treatment recommendations are used to assess anti-immunological therapies.
 24. The drug treatment assay system of claim 21, wherein the rate of death of the live cancer cells testing includes a spectrophotometric analysis at different intervals configured to collect optical density readings and/or cell count numbers for total testing times.
 25. The drug treatment assay system of claim 21, wherein the processor analyzing the measured rates of death of the live cancer cells is configured for analyzing patient genomic testing for detecting genetic markers associated with cancer, drug resistance and allergy and in parallel assess where DNA mutations exists including in a tumor and bloodline mutations.
 26. The drug treatment assay system of claim 21, wherein the testing device is configured to infuse at least one drug treatment including a single drug or a combination of drugs.
 27. The drug treatment assay system of claim 21, wherein the optical density device is configured for measuring an increase of immune antigen stimulation to kill cancer cells and release of antigens to a patient's immune system.
 28. An apparatus, comprising: a purification isolation device configured for isolating live cancer cells of a patient biopsy sample from non-cancer cells and dead cancer cells; a testing device coupled to the purification isolation device configured to infuse a drug or plurality of drugs to the live cancer cells; a digital processor coupled to the testing device configured to analyze testing results with patient genomic testing for detecting genetic markers associated with cancer, drug resistance and allergies; an optical density device coupled to the testing device configured for measuring rates of death of the live cancer cells; at least one correlation module coupled to the optical density device configured to correlate the rate of death of the live cancer cells testing with each drug infusion results; a digital processor coupled to the testing device configured to analyze testing results with patient genomic testing for detecting genetic markers associated with cancer, drug resistance and allergies; and at least one computer coupled to the at least one correlation module configured for generating clinician treatment recommendations to treat a patient with the drug infusion with a highest rate of death of the live cancer cells and transmitting the clinician treatment recommendations to the clinician for consideration for the patient's treatment.
 29. The apparatus of claim 28, further comprising a network coupled with the at least one computer configured to automatically collect prior drug treatment outcomes data from patients and clinicians for analyzing effects on testing results.
 30. The apparatus of claim 28, wherein the optical density device is configured to automatically repeat an optical density analysis of the rate of death of the live cancer cells at different intervals for a predetermined time.
 31. The apparatus of claim 28, wherein a group of a single drug and a combination of drugs includes chemotherapy drugs, legal cannabinoids/CBD drugs, and immunotherapy drugs.
 32. The apparatus of claim 28, wherein at least one correlation module is configured for identifying cannabinoid/CBD anti-tumor effects, immune-activity effects and enhancement of other drug anti-tumor effects.
 33. The apparatus of claim 28, further comprising an optical microplate spectrophotometric reader coupled to the optical density device configured for measuring an increase of immune antigen stimulation treatment to kill live cancer cells and release of antigens to a patient's immune system.
 34. A drug treatment evaluation method, comprising: detecting and isolating live cancer cells from dead cancer cells and non-cancer cells of a biopsy sample of a patient; infusing at least one drug treatment to the live cancer cells; measuring a rate of death of the live cancer cells at different intervals for a predetermined period of time after infusing the at least one drug treatment; analyzing the measured rate of death of the live cancer cells; and using the analyzed rate of death to generate clinician treatment recommendations for the patient's treatment based on the analyzed rate of death of the live cancer cells results.
 35. The drug treatment evaluation method of claim 34, wherein measuring the rate of death of the live cancer cells includes collecting optical density readings and cell count numbers for total testing times.
 36. The drug treatment evaluation method of claim 34, further comprising analyzing patient genomic testing for detecting genetic markers associated with cancer, drug resistance and allergy.
 37. The drug treatment evaluation method of claim 34, further comprising collecting prior drug treatment outcomes data from patients and clinicians.
 38. The drug treatment evaluation method of claim 34, wherein measuring the rate of death of the live cancer cells includes analyzing patient genomic testing for detecting genetic markers associated with cancer, drug resistance and allergies to assess the measured rate of death of the live cancer cells of drug treatments specific to that patient's current condition including genetics and prior treatment affects.
 39. The drug treatment evaluation method of claim 34, wherein measuring a rate of death of the live cancer cells includes collecting optical density readings and cell count numbers for total testing times.
 40. The drug treatment evaluation method of claim 34, wherein measuring the rate of death of the live cancer cells includes measuring a patient's at least one drug treated live cancer cells molecule release into a supernatant culture fluid including at least one from a group consisting of a protein, antigen, and cell component molecule. 